We are live on ! Find out more
CVS icon

CVS Health

1,911 hedge funds and large institutions have $60.6B invested in CVS Health in 2024 Q2 according to their latest regulatory filings, with 132 funds opening new positions, 572 increasing their positions, 1,041 reducing their positions, and 368 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more call options, than puts

Call options by funds: $1.63B | Put options by funds: $1.26B

1.83% more ownership

Funds ownership: 79.82%81.65% (+1.8%)

12% less funds holding

Funds holding: 2,1771,911 (-266)

24% less capital invested

Capital invested by funds: $79.9B → $60.6B (-$19.3B)

34% less funds holding in top 10

Funds holding in top 10: 4127 (-14)

45% less repeat investments, than reductions

Existing positions increased: 572 | Existing positions reduced: 1,041

64% less first-time investments, than exits

New positions opened: 132 | Existing positions closed: 368

Holders
1,911
Holders Change
-266
Holders Change %
-12.22%
% of All Funds
27.6%
Holding in Top 10
27
Holding in Top 10 Change
-14
Holding in Top 10 Change %
-34.15%
% of All Funds
0.39%
New
132
Increased
572
Reduced
1,041
Closed
368
Calls
$1.63B
Puts
$1.26B
Net Calls
+$367M
Net Calls Change
+$332M
Name Holding Trade Value Shares
Change
Change in
Stake
QCM
676
Quantinno Capital Management
New York
$2.28M -$1.56M -24,899 -39%
NIM
677
Northeast Investment Management
Massachusetts
$2.27M -$8.82M -141,025 -79%
UH
678
Unigestion Holding
Switzerland
$2.26M
HPC
679
HM Payson & Co
Maine
$2.24M -$16.5M -264,036 -87%
SPC
680
Sigma Planning Corp
Michigan
$2.24M -$694K -11,090 -23%
CS
681
Crescent Sterling
Louisiana
$2.23M -$202K -3,233 -8%
CG
682
Caprock Group
Idaho
$2.23M +$504K +8,051 +27%
AW
683
Apricus Wealth
South Carolina
$2.23M -$19.4K -310 -0.8%
RAM
684
Roanoke Asset Management
New Jersey
$2.23M -$48.9K -782 -2%
BF
685
BOK Financial
Oklahoma
$2.22M -$165K -2,636 -7%
ECM
686
Elgethun Capital Management
South Dakota
$2.22M -$29.7K -475 -1%
TIAA Trust, National Association
687
TIAA Trust, National Association
North Carolina
$2.21M -$218K -3,483 -9%
IWC
688
Integrated Wealth Concepts
Massachusetts
$2.19M +$290K +4,637 +14%
GRP
689
Global Retirement Partners
California
$2.19M +$282K +4,504 +14%
KOC
690
Koss-Olinger Consulting
Florida
$2.19M +$2.32M +37,025 New
PL
691
Perpetual Ltd
Australia
$2.18M +$691K +11,041 +43%
HSA
692
HBK Sorce Advisory
Pennsylvania
$2.16M -$793K -12,675 -26%
CP
693
Coho Partners
Pennsylvania
$2.15M -$113M -1,807,992 -98%
ATS
694
Ashton Thomas Securities
New York
$2.15M +$2.34M +37,438 New
TPCW
695
TD Private Client Wealth
New York
$2.15M +$679K +10,847 +42%
NCM
696
Narwhal Capital Management
Georgia
$2.15M -$133K -2,127 -6%
CNFG
697
Creegan & Nassoura Financial Group
New Hampshire
$2.15M
Qube Research & Technologies (QRT)
698
Qube Research & Technologies (QRT)
United Kingdom
$2.15M +$2.17M +34,676 +2,045%
TIM
699
Thor Investment Management
Ohio
$2.15M +$157K +2,508 +7%
USAA
700
United Services Automobile Association
Texas
$2.13M -$131K -2,100 -6%

CVS Hedge Fund Activity: Q2 2024 in Review

1,911 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q2 2024, worth a combined $60.6B — down 24% from $79.9B a quarter earlier.

Sellers outnumbered buyers: 368 funds closed out of CVS and 132 opened new positions — a net loss of 236 holders — while 1,041 trimmed existing stakes and 572 added.

The largest buyer was Capital Research Global Investors, adding an estimated $1.4B. The largest seller was Capital International Investors, cutting an estimated $1.07B.

  • 1,911 institutional investors held CVS Health (CVS) as of Q2 2024, down from 2,177 in Q1 2024.
  • Funds reported $60.6B of CVS Health stock for Q2 2024, down 24% quarter-over-quarter.
  • 132 funds opened new CVS Health positions in Q2 2024 and 368 closed out, a net change of -236 holders.
  • The largest CVS Health buyer in Q2 2024 was Capital Research Global Investors, an estimated $1.4B added.
  • The largest CVS Health seller in Q2 2024 was Capital International Investors, an estimated $1.07B sold.

Based on aggregated 13F filings for Q2 2024.